Immunome (IMNM)
NASDAQ:IMNM
Top Page
Immunome
(NASDAQ:IMNM)
Select Model
Select Model
Rating:46Neutral
Price Target:
$21.50
▼(-4.95% Downside)
Action:ReiteratedDate:04/01/26
The score is driven primarily by weak financial performance (declining revenue, large ongoing losses, and significant cash burn), partially offset by a strong low-debt balance sheet. Technical indicators are also bearish/weak (negative MACD with low RSI/Stoch), while valuation offers limited support given a negative P/E and no dividend yield.
Positive Factors
Low leverage / strong liquidity flexibility
Very low debt levels materially reduce refinancing and interest-rate risk, giving management optionality to fund R&D and pursue partnerships or acquisitions. This durable capital structure improves survival odds through clinical cycles and supports strategic investment without near-term debt pressure.
Negative Factors
Persistent and widening cash burn
Sustained large negative operating cash flow forces repeated external financing to sustain development. That dependence increases dilution risk, constrains strategic choices, and requires continual capital markets access; absent milestone receipts, funding needs remain a structural vulnerability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong liquidity flexibility
Very low debt levels materially reduce refinancing and interest-rate risk, giving management optionality to fund R&D and pursue partnerships or acquisitions. This durable capital structure improves survival odds through clinical cycles and supports strategic investment without near-term debt pressure.
Read all positive factors
Immunome (IMNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.45B
Dividend YieldN/A
Average Volume (3M)1.41M
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue Growth-4.44%
EPS Growth63.58%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.76
Shares Outstanding113,133,200
10 Day Avg. Volume1,361,325
30 Day Avg. Volume1,411,535
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue192.74
Enterprise Value/Gross Profit-30.58
Enterprise Value/Ebitda-6.41
Forecast
1Y Price Target
$35.36Price Target Upside56.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.4
Revenue Forecast (FY)$9.83M
Immunome Business Overview & Revenue Model
Company Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of ...
How the Company Makes Money
Immunome primarily makes money through funding and external collaborations rather than product sales, as it is a clinical-stage company with no marketed therapeutics. Key revenue sources include: (1) Collaboration and license revenue: payments rec...
Immunome Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.94M | 9.04M | 14.02M | 0.00 | 0.00 |
| Gross Profit | 3.99M | 9.04M | 14.02M | 0.00 | 0.00 |
| EBITDA | -211.16M | -151.35M | -28.00M | -36.27M | -24.45M |
| Net Income | -212.39M | -292.96M | -106.81M | -36.90M | -24.71M |
Balance Sheet | |||||
| Total Assets | 683.19M | 240.24M | 148.54M | 24.05M | 57.92M |
| Cash, Cash Equivalents and Short-Term Investments | 653.48M | 217.30M | 138.14M | 20.32M | 49.23M |
| Total Debt | 3.85M | 4.83M | 1.65M | 291.00K | 317.00K |
| Total Liabilities | 48.84M | 59.08M | 28.66M | 7.39M | 9.74M |
| Stockholders Equity | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M |
Cash Flow | |||||
| Free Cash Flow | -200.60M | -164.30M | -8.40M | -28.94M | -18.30M |
| Operating Cash Flow | -190.92M | -110.79M | -7.57M | -28.69M | -18.23M |
| Investing Cash Flow | 60.80M | -85.06M | -30.48M | -248.00K | -79.00K |
| Financing Cash Flow | 640.36M | 240.53M | 116.41M | 32.00K | 27.77M |
Immunome Technical Analysis
Positive
22.62
Price Trends
22.07
Positive
21.49
Positive
16.60
Positive
Market Momentum
0.16
Negative
57.38
Neutral
75.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 22.62 is above the 20-day moving average (MA) of 21.04, above the 50-day MA of 22.07, and above the 200-day MA of 16.60, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 57.38 is Neutral, neither overbought nor oversold. The STOCH value of 75.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.
Immunome Risk Analysis
Immunome disclosed 78 risk factors in its most recent earnings report. Immunome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immunome Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $2.85B | -10.13 | -50.30% | ― | 53.28% | 21.77% | |
54 Neutral | $1.07B | ― | -34.23% | ― | 522.13% | 62.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.40B | -5.79 | -39.69% | ― | -27.61% | -69.49% | |
49 Neutral | $1.29B | -16.13 | -56.64% | ― | -36.36% | -945.72% | |
46 Neutral | $2.45B | -8.83 | -57.61% | ― | -4.44% | 63.58% | |
44 Neutral | $824.62M | -4.22 | -141.99% | ― | ― | 31.16% |
* Healthcare Sector Average
IMNM
Immunome
22.62
15.27
207.76%
GERN
Geron
1.73
0.41
31.06%
IMTX
Immatics
10.87
6.64
156.97%
TNGX
Tango Therapeutics
21.56
20.22
1508.96%
TSHA
Taysha Gene Therapies
4.42
3.14
245.31%
SANA
Sana Biotechnology
3.21
1.40
77.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.